Opinion · 22 Oct 2024
Conference abstractPublished 2018
Neurological disorders: Application of nano biotechnology to drug delivery through the blood brain barrier
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
There are approximately 400 known neural disorders, some being due to a disruption or failure of the blood brain barrier (BBB) such as e.g., meningitis, epilepsy, multiple sclerosis, prion and prionlike diseases (Parkinson’s, Alzheimer’s), HIV encephalitis, and systemic inflammation (sterile or infectious). As a consequence of the growing aging population, many such neurodegenerative diseases, cancer, and infections of the brain will become more prevalent. Unfortunately, the developmental process for new drugs has not kept pace with progress in molecular neuroscience because most of the new drugs discovered are unable to cross the BBB. This clinical failure may be largely attributed to a lack of appropriate drug delivery systems. Of interest here are those disorders requiring treatment by delivery of nano biotechnology (NBT)-based drugs through the BBB - one of the most promising applications in clinical neuroscience. Nanoparticles, utilized as drug delivery agents, could potentially carry out multiple tasks in a predefined sequence. They can be effective careers in delivery of conventional drugs, recombinant proteins, vaccines, etc. The following nano technologies are available: liposomes, peptides, radio labeled polyethylene glycol coated hexadecylcyanoacrylate nanospheres, polyalkylcyanoacrylate or poly-lactic-co-glycolic acid (PLGA) nanoparticles with polysorbate 80 or poloxamer and magneto-electric nanoparticles (MENs). Localized and controlled delivery of drugs at their desired sites of action is preferred because it reduces toxicity and increases treatment efficiency. The author will discuss various strategies that have been explored to increase drug delivery into the brain and their attending difficulties, with particular emphasis on NBT based drug delivery systems. However, although the use of nano technology is expected to reduce the need for invasive procedures for delivery of therapeutics, some devices such as implanted catheters and reservoirs will still be needed. Further, there is some concern about the safety of nano particle entry in the brain and this need to be resolved before human use.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in International Journal of Drug Development and Research.
Opinion · 22 Oct 2024
From Monoclonal Antibodies to CAR-T Therapy: Trends and Transformations in Cancer Treatment
Perspective · 21 Oct 2024
Natural Products in Drug Discovery: From Traditional Remedies to Modern Medicines
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Drug Development and Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Alain L Fymat”
